Coelenterazine CAS NO.55779-48-1

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

Coelenterazine is widely distributed among marine organisms, producing bioluminescence calcium-dependent oxidation mediated by the photoprotein aequorin, with EC₅₀ of 257 nM. IC50 & Target: EC50: 257 nM. In Vitro: On addition of coelenterazine to the buffer, intact KB 3-1 Rluc cells show high bioluminescence, whereas intact KB 8-5-11 Rluc cells showe low bioluminescence. A specific Pgp-mediated reduction in steady-state content of coelenterazine existed in KB 8-5-11 Rluc cells compare to KB 3-1 Rluc cells. Bioluminescence signals from KB 3-1 Rluc cells, both in the absence and presence of GF120918 (300 nM), are readily detected with as little as 1 nM extracellular coelenterazine and increase in a concentration-dependent manner to 1 μM extracellular coelenterazine. In Pgp-expressing cells, there is evidence for a GF120918-reversible concentration-dependent saturation of bioluminescence with an EC50 of 257 nM coelenterazine. The plateau in bioluminescence signal observe in KB 8-5-11 Rluc cells implies hat the capacity of Pgp to limit delivery of coelenterazine to cytosolic Rluc is not exceeded within the concentration range test. In Vivo: We then attempt to examine Pgp transport activity and the pharmacodynamics of inhibitors in vivo with noninvasive bioluminescence imaging. Tumor xenografts of KB 3-1 and KB 8-5-11 cells (control tumors) and KB 3-1 Rluc and KB 8-5-11 Rluc cells are grown in nu/nu mice and image with an in vivo imaging system and a charge-coupled device camera. Before tail vein administration of coelenterazine (4 μg/g) and imaging, mice are either first gavaged with vehicle, or the following day, the same mice are gavaged with GF120918 (250 mg/kg), thus enabling each mouse to serve as its own control. At baseline, KB 3-1 Rluc tumors show a 4-fold higher bioluminescence signal in vivo than KB 8-5-11 Rluc tumors. Normalized to bioluminescence signals arising from KB 3-1 Rluc tumors, signals emitte from KB 8-5-11 Rluc tumors in vivo are consistently reduced by≈75% .